ArticleNature2024
Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed.
- A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.Nature communications · 2026Trial
- Engineering "off-the-shelf" TCR-T cells: A transient mRNA platform for balanced alloreactivity and functionality.Molecular therapy. Oncology · 2026Article
- Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors.Cell reports. Medicine · 2026Article
- Metabolic profiling of CAR T-cells in patients reveals a shift toward amino acid-supported OXPHOS and informs transporter engineering.Research square · 2026Article
- Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion.Nature communications · 2026Article
- Radiation-induced CD200Cellular & molecular immunology · 2026Article
- Harnessing macrophage signaling pathways and scalable engineering for next-generation immunotherapies.Signal transduction and targeted therapy · 2026Review
- Depletion of CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- The transcription factor IRF8 drives tumor-specific exhaustion in CD8+ T cells.The Journal of experimental medicine · 2026Article
- Decoding T cell exhaustion in the tumour microenvironment.Experimental & molecular medicine · 2026Review
- Review
- Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy.Biomarker research · 2026Review
- Transcriptomic landscape of peripheral T cells following CAR-T cell therapy in diffuse large B cell lymphoma.Cancer immunology, immunotherapy : CII · 2026Article
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- Advancing clinical precision medicine via peripheral blood immune single-cell omics.Clinical and translational medicine · 2026Article
- Mapping clinical CAR-T cells: insights from scRNA-seq.Trends in molecular medicine · 2026Review
- Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders.Nature reviews. Clinical oncology · 2026Review
- Engineering T cell therapies for lung cancer.Molecular therapy. Oncology · 2026Article
- Article
- Comprehensive analysis of metabolic reprogramming-related gene signatures for predicting ovarian cancer prognosis, the immune landscape, and potential treatment options.Discover oncology · 2026Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Zhiliang Bai *Department of Biomedical Engineering, Yale University, New Haven, CT, USA.ORCID 0000-0002-3977-3057
Bing Feng *Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID 0000-0002-6108-2017
Susan E McCloryDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Beatriz Coutinho de OliveiraLerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Caroline DiorioDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Céline GregoireLerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Bo TaoDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-5490-4668
Luojia YangDepartment of Genetics, Yale University School of Medicine, New Haven, CT, USA.
Ziran ZhaoLerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Lei PengDepartment of Genetics, Yale University School of Medicine, New Haven, CT, USA.
Giacomo SferruzzaDepartment of Genetics, Yale University School of Medicine, New Haven, CT, USA.
Liqun ZhouDepartment of Genetics, Yale University School of Medicine, New Haven, CT, USA.
Xiaolei ZhouInstitute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Jessica KerrLerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Alev BaysoyDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Graham SuDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Mingyu YangDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Pablo G CamaraDepartment of Genetics and Institute for Biomedical Informatics, University of Pennsylvania, Philadelphia, PA, USA.
Sidi ChenDepartment of Genetics, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-3819-5005
Li TangInstitute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. li.tang@epfl.ch.ORCID 0000-0002-6393-982X
Carl H JuneDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.ORCID 0000-0003-0241-3557
J Joseph MelenhorstLerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. melenhj@ccf.org.ORCID 0000-0001-7677-537X
Stephan A GruppDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. grupp@chop.edu.ORCID 0000-0001-8030-7595
Rong FanDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA. rong.fan@yale.edu.ORCID 0000-0001-7805-8059
Funding
Defining and overcoming intrinsic T cell dysfunction to enable pediatric immunotherapyU01CA232361 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI GRUPP, STEPHAN A., WEBER, EVAN WILLIAM · 2019 to 2019
$3.7MLinking insertional mutagenesis and cell function to improve CAR T cell therapyR01CA241762 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BUSHMAN, FREDERIC D, MELENHORST, JAN J · 2019 to 2023
$3.1MA data-driven bioinformatics platform for the design and analysis of multiplexed antibody-based cytometry experiments in cancer researchU01CA269409 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GONZALEZ CAMARA, PABLO · 2022 to 2024
$1.0MCalming the Cytokine Storm: Unraveling the Biology of CRS and ICANSK08CA286762 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI Caroline Diorio · 2024 to 2026
$746kNCI NIH HHS K08 CA286762NCI NIH HHS R01 CA241762NCI NIH HHS U01 CA232361NCI NIH HHS U01 CA269409
Abstract
Despite a high response rate in chimeric antigen receptor (CAR) T cell therapy for acute lymphocytic leukaemia (ALL)
Indexed as
Immunotherapy, AdoptiveMultiomicsPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenRemission InductionSingle-Cell AnalysisAnimalsChildCytokinesDisease Models, AnimalEpigenomicsGene Expression ProfilingHumansInterleukin-4MiceMice, Inbred NODCytokinesInterleukin-4Receptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.